Last updated: July 31, 2026
Ondansetron hydrochloride and dextrose in a plastic container is a generic premixed intravenous antiemetic product, generally supplied as ondansetron hydrochloride in 5% dextrose injection. The product is used to prevent nausea and vomiting associated with moderately or highly emetogenic cancer chemotherapy, radiotherapy, and postoperative recovery. It is an established generic product with limited clinical-development activity, low formulation differentiation, and substantial price competition.
No publicly identifiable late-stage clinical program is focused on the premixed ondansetron-and-dextrose product as a new therapy. Commercial performance depends primarily on hospital procurement, supply reliability, contract pricing, manufacturing cost, and availability of competing ondansetron injection presentations.
What is ondansetron hydrochloride and dextrose in a plastic container?
Ondansetron hydrochloride is a selective 5-HT3 receptor antagonist. The dextrose solution is the intravenous vehicle. The plastic container is a packaging and delivery format rather than a separate active pharmaceutical technology.
| Attribute |
Product profile |
| Active ingredient |
Ondansetron hydrochloride |
| Pharmacologic class |
Selective serotonin 5-HT3 receptor antagonist |
| Route |
Intravenous infusion |
| Common vehicle |
5% dextrose injection |
| Dosage forms |
Premixed single-dose intravenous container |
| Primary users |
Hospitals, oncology centers, ambulatory surgery centers |
| Main indications |
Chemotherapy-induced nausea and vomiting, radiotherapy-induced nausea and vomiting, postoperative nausea and vomiting |
| Regulatory category |
Generic prescription drug |
| Biosimilar relevance |
None; ondansetron is a small molecule |
| Main competitors |
Generic ondansetron injection, ondansetron hydrochloride injection in saline, oral ondansetron, orally disintegrating tablets, and other antiemetics |
The product is administered intravenously and is typically supplied in flexible plastic containers. Product-specific strengths and container volumes vary by manufacturer and market.
What is the FDA regulatory status of ondansetron hydrochloride and dextrose?
Ondansetron injection products are approved under abbreviated or generic drug pathways, depending on the specific applicant and presentation. The reference product is Zofran injection, originally developed by GlaxoSmithKline. Generic products do not require new efficacy trials if they demonstrate pharmaceutical equivalence and bioequivalence, or otherwise satisfy the applicable FDA requirements for injectable products.
The premixed dextrose presentation is regulated as a finished dosage form. It must satisfy requirements covering:
- Sterility and bacterial endotoxin limits
- Strength and assay
- Particulate matter
- Container-closure integrity
- Stability and expiration dating
- Compatibility of ondansetron with the dextrose vehicle
- Labeling and administration instructions
The principal regulatory risk is manufacturing compliance rather than clinical efficacy. A sterile-product warning letter, recall, shortage, or facility interruption can affect commercial supply even when demand is stable.
What indications are included in the labeling?
Ondansetron injection labeling generally covers:
- Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy.
- Prevention of nausea and vomiting associated with radiotherapy.
- Prevention of postoperative nausea and vomiting.
The approved label includes age-specific dosing and warnings concerning QT interval prolongation, serotonin syndrome, hypersensitivity, and use in patients with electrolyte abnormalities or relevant cardiac risk factors. The product is not interchangeable with every ondansetron presentation on a unit-for-unit basis because concentration, container volume, dosing instructions, and administration requirements differ.
What clinical trials are evaluating ondansetron hydrochloride and dextrose?
No significant late-stage clinical trial activity is associated specifically with the premixed ondansetron hydrochloride-and-dextrose container. Ondansetron has an extensive historical clinical-trial record, but most studies evaluate the active ingredient across different routes, doses, patient populations, or combination regimens.
Clinical development status
| Clinical area |
Current status |
| New efficacy trial for the premixed plastic-container product |
No meaningful public development program identified |
| Generic approval studies |
Primarily pharmaceutical quality, equivalence, and product-specific regulatory studies |
| Chemotherapy-induced nausea and vomiting |
Established indication |
| Postoperative nausea and vomiting |
Established indication |
| Pediatric use |
Labeling and clinical evidence depend on age and indication |
| New formulation development |
Limited commercial rationale because multiple generic presentations exist |
| Biosimilar development |
Not applicable |
ClinicalTrials.gov records for ondansetron include studies in postoperative nausea, pregnancy-associated nausea, gastroenteritis, opioid-related nausea, chemotherapy, and other conditions. These studies do not establish a new regulatory pathway for the premixed product and generally do not create exclusivity.
The central clinical issue is established efficacy rather than unmet efficacy. New trials would have limited commercial value unless they support a differentiated delivery system, a new indication, reduced cardiac risk, or a meaningful administration advantage.
What patents protect ondansetron hydrochloride and dextrose in a plastic container?
The original composition-of-matter protection for ondansetron expired years ago. The product is therefore exposed to generic competition.
The potentially relevant intellectual-property categories are:
- Historical compound patents covering ondansetron
- Historical pharmaceutical-composition patents
- Formulation patents covering concentration, stability, or excipients
- Container-closure and packaging patents
- Manufacturing-process patents
- Method-of-use patents for specific antiemetic applications
For the standard generic premixed product, no broadly blocking, commercially significant patent estate is generally associated with the active ingredient. Any product-specific patents would need to be evaluated by applicant, strength, formulation, container design, and jurisdiction.
Is the product listed in the Orange Book?
Ondansetron drug products may appear in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book, under the relevant product and dosage-form listings. Orange Book status must be checked at the specific application, strength, route, and dosage-form level.
An Orange Book listing does not mean that a particular plastic container, dextrose concentration, or packaging configuration has meaningful patent protection. Patent listings are application-specific and may not cover every generic premixed presentation.
How strong is the patent estate?
The patent estate is weak from a lifecycle-management perspective:
| Patent category |
Risk assessment |
| Active ingredient |
Low risk; foundational protection expired |
| Standard injectable formulation |
Low to moderate, depending on product-specific claims |
| Dextrose vehicle |
Low |
| Plastic container |
Low to moderate; packaging claims may be narrow |
| Manufacturing process |
Moderate only if a non-obvious process is claimed and commercially necessary |
| Method of use |
Low for established labeled uses |
| Biosimilar barriers |
None |
A narrow formulation or container patent could delay a specific competitor without protecting the broader ondansetron market. Such patents are less likely to support premium pricing when hospitals can purchase alternative ondansetron concentrations, vehicles, or dosage forms.
When does ondansetron lose exclusivity?
Ondansetron’s principal market exclusivity expired before the current generic era. The product is already in the post-exclusivity phase.
| Exclusivity element |
Status |
| New chemical entity exclusivity |
Expired |
| Original compound patent protection |
Expired |
| Generic entry |
Established |
| Current market |
Mature generic |
| Pediatric exclusivity |
Not a current barrier to ordinary generic supply |
| Orphan-drug exclusivity |
Not applicable to the standard product |
| Biosimilar exclusivity |
Not applicable |
The relevant commercial question is not the date of first generic entry. It is whether a manufacturer can maintain supply, secure hospital contracts, and avoid quality-related disruption.
Which companies compete in the ondansetron injection market?
The competitive landscape includes branded legacy suppliers, large generic manufacturers, hospital-focused injectable companies, and outsourcing facilities. Depending on the jurisdiction and product strength, suppliers may include:
- Fresenius Kabi
- Pfizer and Hospira affiliates
- Hikma Pharmaceuticals
- Sandoz
- Teva Pharmaceuticals
- Baxter, where the relevant premixed or infusion presentation is marketed
- Other approved generic injectable manufacturers and contract suppliers
Supplier participation changes over time because sterile injectable manufacturing is vulnerable to plant closures, inspections, recalls, raw-material shortages, and allocation decisions.
How does the premixed product compare with other ondansetron products?
| Product type |
Clinical convenience |
Manufacturing complexity |
Price pressure |
Hospital relevance |
| Premixed ondansetron in dextrose |
High |
High |
High |
High where ready-to-administer products are preferred |
| Ondansetron injection in saline |
Moderate |
High |
High |
High |
| Ondansetron injection requiring dilution |
Lower |
Moderate to high |
High |
Moderate |
| Oral tablet |
High for suitable patients |
Lower |
Very high |
High |
| Orally disintegrating tablet |
High |
Lower |
High |
Moderate to high |
| Oral solution |
Moderate |
Moderate |
High |
Pediatric and selected outpatient use |
Premixed products can reduce pharmacy compounding steps and medication-preparation time. Their disadvantages include higher packaging and logistics costs, shorter or more restrictive storage conditions in some configurations, and lower flexibility in dose selection.
What is the market outlook for ondansetron hydrochloride and dextrose?
Public company filings generally do not report revenue for ondansetron hydrochloride and dextrose in plastic containers as a standalone product. The market is usually included within broader categories such as hospital injectables, antiemetics, generic sterile products, or intravenous solutions.
The product is best classified as a mature, low-growth generic hospital injectable. Demand is supported by:
- Continued chemotherapy administration
- Surgical procedures requiring postoperative nausea prevention
- Emergency and inpatient use
- Standardized hospital antiemetic protocols
- Preference for ready-to-use or ready-to-administer products
Demand is constrained by:
- Low unit pricing
- Therapeutic substitution with oral products
- Use of other antiemetics, including palonosetron, granisetron, aprepitant, dexamethasone, and olanzapine
- Hospital purchasing consolidation
- Generic tender competition
- Periodic sterile-injectable shortages
Five-year market projection
A reasonable base case is a flat-to-low-single-digit annual revenue outlook for the specific premixed product in mature markets. Volume can remain stable while revenue declines because of price erosion.
| Scenario |
Volume outlook |
Pricing outlook |
Revenue outlook |
Main drivers |
| Downside |
-3% to -6% annually |
-4% to -8% annually |
-7% to -13% annually |
Additional generic entry, oral substitution, contract repricing |
| Base case |
0% to 2% annually |
-2% to -5% annually |
-1% to -5% annually |
Stable hospital demand with continued price pressure |
| Upside |
2% to 4% annually |
0% to -2% annually |
0% to 4% annually |
Supply shortages, ready-to-use procurement preference, improved hospital utilization |
These are scenario ranges rather than reported market-size estimates. The product’s commercial value is more sensitive to manufacturing reliability and contract wins than to clinical-trial outcomes.
What generic entry risks affect the product?
Generic-entry risk is already realized. The principal future risks are competitive and operational:
- New approved suppliers can reduce contract prices.
- A hospital system can substitute saline-based ondansetron or another antiemetic.
- Pharmacy automation can reduce the value of a premixed container.
- A competitor can offer a lower-cost container or larger contract package.
- FDA manufacturing action can remove a supplier from the market.
- Hospital formularies can favor oral therapy where clinically appropriate.
- A shortage at one supplier can shift demand rapidly to another.
Paragraph IV litigation is unlikely to be a central issue for the legacy standard product because foundational patents have expired and the market has already experienced generic entry. A Paragraph IV filing could still arise against a later, narrow formulation or packaging patent, but such litigation would likely concern a specific product configuration rather than the active ingredient broadly.
What licensing deals and settlement agreements affect ondansetron?
No major current licensing arrangement or settlement agreement is generally required to commercialize standard generic ondansetron injection. The original innovator licensing and commercialization arrangements are historical and do not create a current barrier to ordinary generic supply.
Commercial arrangements are more likely to involve:
- Hospital group purchasing organizations
- Wholesale distribution
- Contract manufacturing
- Private-label supply
- Formulary agreements
- Regional distribution rights
These agreements can materially affect market share without changing patent status.
What manufacturing and geographic barriers exist?
The strongest barriers are operational rather than intellectual property-based. Sterile injectable production requires validated aseptic processing, qualified filling equipment, container-closure controls, environmental monitoring, and reliable quality systems.
Geographic market access also depends on:
- Local drug registration
- Import and serialization requirements
- National tender systems
- Hospital procurement rules
- Local sterile manufacturing capacity
- Reimbursement and substitution rules
The United States is likely to remain a price-competitive market. Emerging markets may offer higher unit growth but have greater exposure to local registration, tender pricing, and distribution risks.
Key Takeaways
- Ondansetron hydrochloride and dextrose in a plastic container is a mature generic intravenous product.
- No meaningful new clinical-trial program is focused on the premixed product itself.
- The active ingredient and original compound protection are long expired.
- Biosimilar risk is irrelevant because ondansetron is a small molecule.
- Patent risk is limited to narrow formulation, packaging, or manufacturing claims.
- Paragraph IV litigation is unlikely to materially affect the established market.
- Revenue growth is likely to be flat or negative because of generic price erosion.
- Hospital demand remains supported by oncology, surgery, and inpatient antiemetic use.
- Supply reliability, FDA manufacturing compliance, and hospital contracting are the primary commercial differentiators.
- The base-case five-year revenue outlook is approximately flat to down low single digits annually, absent a shortage or supply disruption.
FAQs
Is ondansetron hydrochloride in dextrose the same as Zofran?
It contains the same active ingredient, ondansetron hydrochloride, but a generic premixed product may differ in concentration, container, labeling, manufacturer, and inactive ingredients. Zofran is the historical branded reference product.
Can ondansetron hydrochloride and dextrose be substituted for ondansetron in saline?
Clinical substitution depends on concentration, dose, administration instructions, patient condition, pharmacy policy, and product labeling. The products are not automatically interchangeable solely because they contain ondansetron.
Does ondansetron hydrochloride have biosimilar competition?
No. Biosimilars apply to biological products. Ondansetron is a chemically synthesized small molecule and competes through generic-drug pathways.
What is the main commercial advantage of the plastic container?
The main advantage is ready-to-administer intravenous packaging that can reduce pharmacy preparation and handling. The advantage is operational rather than clinically differentiating.
Is the product attractive for pharmaceutical licensing?
Licensing attractiveness is generally limited for an undifferentiated product. Value may exist in a reliable sterile manufacturing platform, a differentiated container, a regional supply agreement, or an established hospital distribution channel.
References
-
DailyMed. (n.d.). Ondansetron hydrochloride injection, solution prescribing information. U.S. National Library of Medicine.
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA.
-
U.S. Food and Drug Administration. (n.d.). Drug shortages: Current and resolved drug shortages. FDA.
-
ClinicalTrials.gov. (n.d.). Search results for ondansetron. National Library of Medicine.
-
GlaxoSmithKline. (n.d.). Zofran (ondansetron hydrochloride) injection prescribing information. U.S. Food and Drug Administration.
